LCM
Lynx1 Capital Management Portfolio holdings
AUM
$346M
This Quarter Return
-17.16%
1 Year Return
-2.97%
3 Year Return
+1,498.67%
5 Year Return
–
10 Year Return
–
AUM
$267M
AUM Growth
+$267M
(-5.5%)
Cap. Flow
+$34M
Cap. Flow
% of AUM
12.76%
Top 10 Holdings %
Top 10 Hldgs %
95.76%
Holding
24
New
6
Increased
5
Reduced
3
Closed
6
Top Buys
| 1 |
Cullinan Oncology
CGEM
|
$10.3M |
| 2 |
Allogene Therapeutics
ALLO
|
$9.95M |
| 3 |
Keros Therapeutics
KROS
|
$8.61M |
| 4 |
GH Research
GHRS
|
$4.64M |
| 5 |
ALLK
Allakos
ALLK
|
$4.39M |
Top Sells
| 1 |
Merus
MRUS
|
$8.96M |
| 2 |
NEUP
Neuphoria Therapeutics Inc. Common Stock
NEUP
|
$1.73M |
| 3 |
Kodiak Sciences
KOD
|
$708K |
| 4 |
PVLA
Palvella Therapeutics, Inc. Common Stock
PVLA
|
$621K |
| 5 |
Kiniksa Pharmaceuticals
KNSA
|
$206K |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Merus
MRUS
$4.98B
| $66.5M | 24.92% |
1,580,841
-213,025
| -12% | -$8.96M |
|
2
Stoke Therapeutics
STOK
$1.08B
| $57.2M | 21.45% |
5,187,191
| – | – |
|
|
3
GH Research
GHRS
$837M
| $34M | 12.75% |
4,858,994
+663,100
| +16% | +$4.64M |
|
4
C4 Therapeutics
CCCC
$185M
| $24.7M | 9.25% |
6,852,744
-27,783
| -0.4% | -$100K |
|
|
5
Allogene Therapeutics
ALLO
$251M
| $23.2M | 8.68% |
10,874,723
+4,672,349
| +75% | +$9.95M |
|
6
TScan Therapeutics
TCRX
$102M
| $16.3M | 6.11% |
5,357,347
+132,747
| +3% | +$404K |
|
|
7
Cullinan Oncology
CGEM
$445M
| $15.3M | 5.74% |
1,257,795
+846,965
| +206% | +$10.3M |
|
|
8
Keros Therapeutics
KROS
$618M
| $8.61M | 3.23% |
+544,001
| New | +$8.61M |
|
9
Passage Bio
PASG
$22.7M
| $5.25M | 1.97% |
9,256,953
+829,998
| +10% | +$471K |
|
|
ALLK
10
DELISTED
Allakos
ALLK
| $4.39M | 1.65% |
+3,628,144
| New | +$4.39M |
|
|
UPB
11
Upstream Bio, Inc. Common Stock
UPB
$923M
| $3.95M | 1.48% |
+240,042
| New | +$3.95M |
|
12
Precision BioSciences
DTIL
$57.8M
| $2.92M | 1.09% |
+766,051
| New | +$2.92M |
|
13
iBio
IBIO
$16.1M
| $2.11M | 0.79% |
862,279
| – | – |
|
14
Caribou Biosciences
CRBU
$174M
| $1.08M | 0.41% |
680,189
| – | – |
|
15
Vor Biopharma
VOR
$250M
| $707K | 0.27% |
+637,218
| New | +$707K |
|
|
CNTA
16
Centessa Pharmaceuticals
CNTA
$2.25B
| $291K | 0.11% |
17,400
| – | – |
|
|
NEUP
17
Neuphoria Therapeutics Inc. Common Stock
NEUP
$21.3M
| $157K | 0.06% |
45,806
-503,867
| -92% | -$1.73M |
|
18
Repare Therapeutics
RPTX
$71.7M
| $104K | 0.04% |
+79,176
| New | +$104K |
|
19
VYNE Therapeutics
VYNE
$8.16M
| – | – |
-16,194
| Closed | -$30.4K |
|
|
PVLA
20
Palvella Therapeutics, Inc. Common Stock
PVLA
$599M
| – | – |
-37,436
| Closed | -$621K |
|
21
Century Therapeutics
IPSC
$42.5M
| – | – |
-19,028
| Closed | -$32.5K |
|
|
22
Kiniksa Pharmaceuticals
KNSA
$2.48B
| – | – |
-8,231
| Closed | -$206K |
|
|
23
Kodiak Sciences
KOD
$478M
| – | – |
-271,177
| Closed | -$708K |
|
24
Tenax Therapeutics
TENX
$27.3M
| – | – |
-14,751
| Closed | -$51K |
|